Bio

David Rosenthal, former co-head of both the firm's Life Sciences Practice and its Global Capital Markets Practice, represents publicly and privately held corporations, investment banks, and venture capital firms focused on the life sciences and medical device, technology, media, and other growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensings and strategic alliances. Mr. Rosenthal regularly advises issuers and investment banks in public and private offerings of equity and debt, including IPOs, secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, registered direct offerings, and PIPEs, as well as seed financings and later-stage venture capital financings. He also has particular experience counseling foreign private issuers in migrating to and listing on the U.S. stock exchanges. Mr. Rosenthal also counsels clients in general corporate matters, Securities and Exchange Commission (SEC) compliance, and corporate governance, and often acts as outside general corporate and securities counsel to both emerging and publicly traded companies. These activities have included business and corporate planning and structuring as well as other contract negotiations, and contractual and other commercial dealings. In the mergers and acquisitions area, Mr. Rosenthal has represented buyers and sellers in leveraged and unleveraged mergers, acquisitions, and private equity transactions as well as divestitures and dispositions of business and subsidiaries. The American Lawyer selected Mr. Rosenthal as Dealmaker of the Week for his skillful representation of Inhibitex in its sale to Bristol-Myers Squibb for US$2.5 billion, which represented a 163 percent premium to the closing price of the company’s stock the day before the transaction signed, and is believed to be one of the largest premiums in deal history. Mr. Rosenthal is routinely recognized by The Legal 500 US for his work in the life sciences industry, most recently in 2024, as well as for capital markets: equity, debt and global offerings. In 2023, clients noted Mr. Rosenthal as “truly exceptional” and someone who “stands out in his field” and “carefully researches matters of relevance." In prior editions of The Legal 500 US, clients praised him as “a trusted and valued advisor” who “seeks to understand the client’s business”, as well as for his “clear and well-reasoned positions” and his “business-minded approach.” He has also been noted for having “an active life sciences roster” with “an immense depth of industry and transactional knowledge in the healthcare sector.” In 2022, Mr. Rosenthal led the team commended by the Financial Times’ Innovative Lawyer Awards for “overcoming barriers to investment and finance” for their role in Tiziana Life Sciences’ cross-border jurisdictional migration from listing on the London Stock Exchange to the NASDAQ. He is consistently named an LMG Life Sciences Star for life sciences transactions. In 2020, Mr. Rosenthal was named a “Dealmaker of the Year” by The American Lawyer for his work conceiving and executing an innovative life sciences restructuring deal on behalf of pharmaceuticals manufacturer Egalet Corporation (subsequently sold to Assertio Therapeutics). In addition, Mr. Rosenthal is routinely recognized as a leading life sciences transactional lawyer by Who’s Who Legal: USA and was named a “highly regarded” lawyer for M&A in the IFLR1000.